Halonova S Ointment is a topical formulation containing Halobetasol propionate 0.05% w/w, a potent corticosteroid, combined with Salicylic Acid 3% w/w, a keratolytic agent. This combination is indicated for the management of inflammatory dermatoses such as psoriasis, eczema, and other corticosteroid-responsive skin disorders characterized by scaling, thickening, and inflammation. Halobetasol exerts strong anti-inflammatory, immunosuppressive, and antipruritic effects by inhibiting multiple inflammatory cytokines and mediators, thereby reducing erythema, edema, and pruritus. Salicylic Acid facilitates the removal of hyperkeratotic scales by softening and promoting the exfoliation of the stratum corneum, enhancing the penetration and efficacy of the corticosteroid. Halonova S Ointment is applied topically in a thin layer to the affected area, usually once or twice daily, as directed by a healthcare professional. It is contraindicated in patients with hypersensitivity to any component, untreated bacterial or fungal infections, and should be used cautiously in areas with thin skin or mucous membranes. Prolonged use may lead to local adverse effects such as skin atrophy, telangiectasia, and systemic absorption-related effects. Patient adherence to prescribed duration and dosage is essential to minimize risks and optimize therapeutic outcomes.